Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Frau

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Journal of Neurology|June 17, 2021
What happens after fingolimod discontinuation? A multicentre real-life experienceDoriana Landi, Alessio Signori, Maria Cellerino, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 10, 2011
Epidemiology of multiple sclerosis in south-western SardiniaEleonora Cocco, Claudia Sardu, Rita Massa, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2026
EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis: Evidence From Integrated Viral and Host AnalysesChiara Meloni, Fabiana Marnetto, Corrado Fagnani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 27, 2014
Influence of treatments in multiple sclerosis disability: a cohort studyEleonora Cocco, Claudia Sardu, Gabriella Spinicci, et al.
Journal of Neurology|April 7, 2017
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG bandDiana Ferraro, Diego Franciotta, Roberta Bedin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
European Journal of Neurology|May 8, 2023
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
Neurology|January 21, 2021
Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple SclerosisGiacomo Boffa, Luca Massacesi, Matilde Inglese, et al.
Journal of Neuroimmunology|August 14, 2023
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Virginia Quaresima, Mosè Barbaro, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Journal of Neurology|June 17, 2021
What happens after fingolimod discontinuation? A multicentre real-life experienceDoriana Landi, Alessio Signori, Maria Cellerino, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 10, 2011
Epidemiology of multiple sclerosis in south-western SardiniaEleonora Cocco, Claudia Sardu, Rita Massa, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2026
EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis: Evidence From Integrated Viral and Host AnalysesChiara Meloni, Fabiana Marnetto, Corrado Fagnani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 27, 2014
Influence of treatments in multiple sclerosis disability: a cohort studyEleonora Cocco, Claudia Sardu, Gabriella Spinicci, et al.
Journal of Neurology|April 7, 2017
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG bandDiana Ferraro, Diego Franciotta, Roberta Bedin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
European Journal of Neurology|May 8, 2023
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
Neurology|January 21, 2021
Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple SclerosisGiacomo Boffa, Luca Massacesi, Matilde Inglese, et al.
Journal of Neuroimmunology|August 14, 2023
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Virginia Quaresima, Mosè Barbaro, et al.
Pageof 11